During the first part of the study, participants are randomly assigned to receive either NIO752 or the placebo. The study is double-blind, which means neither the participants nor the researchers know which substance is being administered. Throughout this period, various measurements are taken to monitor changes in movement, daily activities, and quality of life. Additionally, an MRI, a specialized imaging test that uses magnets to create detailed pictures of the brain, is used to look at different brain structures.

Following the initial phase, there is an open label extension, where participants may have the opportunity to receive the active medication. The study also monitors safety by tracking any side effects or changes in vital signs and electrocardiogram results, which is a test that records the electrical activity of the heart.

Participants in the study will receive an injection of the [18F]PI-2620 solution. After the injection, they will undergo a PET scan, which is a type of imaging test that helps doctors see how the agent is distributed in the brain. This will help researchers understand the differences in brain activity between those with Progressive Supranuclear Palsy, Parkinson’s Disease, and healthy individuals. The study will also look at how these differences relate to various factors like age, clinical symptoms, and other biological markers found in the body.

The study is expected to continue until the end of 2026, with recruitment of participants starting in mid-2024. By participating in this study, researchers hope to gain valuable insights into these neurological conditions, which could lead to better understanding and potentially improved treatments in the future.

The purpose of the study is to see how well these substances can help identify people who are at risk of developing dementia, a condition that affects memory and thinking. Participants in the study will receive an injection of either Vizamyl or [18F]RO6958948. These substances help highlight areas in the brain that may be affected by the disorders. The study will compare the brain scans of people with these disorders to those of healthy individuals to better understand the differences.

Throughout the study, participants will undergo various tests, including brain scans and cognitive assessments, to monitor their brain health and cognitive function. The study aims to gather information over time to see how these disorders progress and how the substances used in the study can aid in early detection and diagnosis. This research hopes to provide valuable insights into the early stages of these disorders and improve the way they are diagnosed and understood.

The purpose of the study is to compare the amount of a specific protein, called tau 4R, in the brains of people with PSP to those without any neurodegenerative conditions. Participants will receive an injection of the [18F]PI-2620 solution, which will help doctors see the tau 4R protein deposits in the brain during the PET scan. The study will also look at how the brain uses sugar, which is important for understanding brain activity, and will assess symptoms related to movement and mood.

Participants in the study will include people diagnosed with PSP and a control group of individuals without neurodegenerative diseases. The study will help researchers understand more about PSP and how it affects the brain, potentially leading to better ways to diagnose and treat this condition in the future.

The study will compare FNP-223 with a placebo to see how effective and safe the medication is for people with PSP. Participants will be randomly assigned to receive either the study medication or placebo, and neither the participants nor the doctors will know which treatment is being given during the study period.

Throughout the 52-week study period, participants will be monitored for changes in their condition using various assessments that measure movement ability, daily activities, thinking skills, and overall quality of life. The study will also track any side effects that may occur during treatment. Regular check-ups will help ensure participant safety and evaluate how well the medication is working.

The purpose of the study is to assess the impact of AMX0035 compared to a placebo on the rate of disease progression. Participants in the study will receive either AMX0035 or a placebo, which is a substance with no active medication. The study will last for a period of time, during which participants will take the treatment orally in the form of a powder. The study will monitor changes in the participants’ condition using a scale called the Progressive Supranuclear Palsy Rating Scale (PSPRS), which measures the severity of symptoms.

Throughout the study, participants will have regular visits to check their health and monitor any changes in their symptoms. The study will also track any side effects or adverse events that may occur. The goal is to determine if AMX0035 can effectively slow down the progression of PSP and improve the quality of life for those affected by this condition.

Participants in the study will receive Bepranemab over an extended period. The study will monitor participants to see if they experience any side effects or changes in their condition. This is an open-label extension study, meaning that all participants will receive the actual treatment rather than a placebo. The study aims to gather information on how well participants tolerate the treatment over time.

The study will continue until 2027, allowing researchers to collect comprehensive data on the long-term effects of Bepranemab in individuals with Progressive Supranuclear Palsy. This information will help determine if the treatment is safe for long-term use and if it can be a viable option for managing this challenging condition.